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ECONOMIC EVALUATION OF PHOTODYNAMIC
THERAPY WITH VERTEPORFIN FOR
PREDOMINANTLY CLASSIC, SUBFOVEAL CNV
SECONDARY TO AGE-RELATED MACULAR
DEGENERATION
Lees M1, Davey P1,Aldridge G1, Schulz M1, Aristides M2
1Medical Technology Assessment Group, Chatswood West,
NSW, Australia; 2Medical Technology Assessment Group,
London, UK
OBJECTIVE: To assess the cost-effectiveness of photo-
dynamic therapy (PDT) with verteporﬁn for the treatment
of predominantly classic, subfoveal choroidal neovascu-
larisation (CNV) secondary to age-related macular 
degeneration (AMD) relative to no treatment.
METHODS: This analysis examines the cost-effectiveness
of PDT using verteporﬁn in patients with predominantly
classic CNV secondary to AMD, based on results of 
the TAP study, a multicentre, double-blind, randomised,
placebo-controlled trial. Data on visual acuity levels were
collected for 24 months, with an option of a further 12
months. Patients with visual acuity scores above the level
of legal blindness in Australia (34 letters or less) were
deﬁned as not blind. The proportion of patients not
legally blind at each three month interval was plotted on
a ‘vision curve’, extrapolated to 60 months and the area
under the curve calculated for each group. The difference
in area under the curve between groups is the vision years
gained from treatment. A costing analysis was also 
performed, based on an average of 3.4 treatments in 
the ﬁrst year, 2.1 in the second year and 1.2 in the third 
year. Costs of permanent nursing home entry, home and
community care, and falls—all resulting from declining
vision—were also included in the analysis.
RESULTS: The incremental cost of PDT with verteporﬁn
compared with no treatment varied between $13,762 and
$15,031 over the ﬁve-year period, depending on assump-
tions made regarding data extrapolation. Vision years
gained over this time varied between 0.7552 and 1.0389.
This corresponds to an incremental cost per vision year
gained of between $13,246 and $19,903, which sen-
sitivity analyses have shown to be robust to changes in
the value of key variables.
CONCLUSIONS: PDT with verteporﬁn represents a cost-
effective intervention in the proposed population. There
is currently no alternative treatment for patients with pre-
dominantly classic, subfoveal CNV secondary to AMD.
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THE PATIENTS’ PERCEPTION OF THEIR
PSORIASIS AND ITS TREATMENT THROUGH A
DIARY
Taieb C, Myon E
PharmacoEconomics Programs, bioMérieux-Pierre Fabre,
Boulogne Billancourt, France
OBJECTIVES: The purpose of this study is to report 
preliminary ﬁndings of patient’s perception of their 
psoriasis and its treatment. SPOT is a longitudinal,
prospective, observational, programme. 2000 patients
with mild to moderate psoriasis will be recruited. (1000
Chronic Psoriasis Patient & 1000 New Psoriasis Patient).
METHODS: In this study, patients record, weekly, in 
a diary, their perception concerning satisfaction with
treatment, its side-effects and how it has been applied.
RESULTS: At this time we received 220 diaries ﬁlled in
during 4 weeks (50.7% of the patients followed since 4
weeks). The 2 populations are balanced. At the end of the
ﬁrst week, 14% of the population is unsatisﬁed with its
treatment and 75% declared an improvement of their
health state. The treatment compliance was evaluated, at
the end of the ﬁrst week 91% of the patients stated that
they are treating themselves 5 days per week or more, and
only 75% of the patients stated it at the end of the fourth
week. In this ﬁrst analysis we essentially focused on the
most often expressed treatment’s side effects: Burning
Sensation -BS-, Tearing Sensation (TS), Itching (I) and
Drying (D). At the end of the fourth week, for each
patient declaring a side-effect during the ﬁrst week, one
can note that the BS is reduced by 80%, the TS by 70%,
the I by 57% and the D by 48%.
CONCLUSION: The ﬁrst results of this program show
evidence of the patients support towards those types of
study and the methodology used. The non persistence 
of the most often expressed treatment’s side effects at 
the end of the 4 ﬁrst weeks demonstrate that a relevant
patient management is an alternative.
PES9
PSORIASIS AND EVERYDAY LIFE: FIRST
RESULTS
Taieb C, Myon E
PharmacoEconomics Programs, bioMérieux-Pierre Fabre,
Boulogne Billancourt, France
OBJECTIVE: To evaluate the effect of psoriasis on
quality of life of patients in France.
METHOD: 4.500 anonymous questionnaires (comprised
of two scales: the Psoriasis Disability Index (PDI) plus 10
questions concerning treatment and evolution of 
psoriasis) were sent, via a Psoriasis Patient Support
Group (APLCP).
RESULTS: 2.423 questionnaires were returned: response
rate 53%. An analysis of the ﬁrst 1866 questionnaires
was realised. The sex ratio Men (M)/Women (W) was:
47/53. Mean age: 51 years. Mean age of diagnosis: 22
years. The average to the total score was 9,64 (sd 5.2 rank
0 to 28) i.e. 21,6 (sd: 12.4) when reported to a scale of
0 to 100. No difference was observed between M and W
for the global handicap score. Psoriasis had a greater
adverse affect on 16–55 year-old patients in their social
relationships, leisure activities and how well they keep
their house than older subjects. Long-standing psoriasis
did not cause more handicap to people than psoriasis
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more recently experienced (similar global score).
However, the age at the time of diagnosis and the level of
incapacity experienced was related (p = 0.015). The
younger the patient is at which psoriasis is diagnosed the
higher the level of handicap is, particularly on the “every-
day” and “leisure” scores.
CONCLUSION: These results highlight the value of
appropriate and relevant psychological and medical 
environment for children suffering from psoriasis.
PES10
THE PSORIASIS MANAGEMENT DURATION
INDUCED DIFFERENCES IN THE DISABILTY’S
REPERCUSSION
Taieb C, Myon E
PharmacoEconomics Programs, bioMérieux-Pierre Fabre,
Boulogne Billancourt, France
Psoriasis is a chronicle disease, which concerns 4.7% of
the French population. Although it does not shorten life
it has major consequences on patients’ daily life because
of the damage to the body image.
OBJECTIVE: The purpose of this study is to report 
preliminary ﬁndings of perceived disability in patients
with psoriasis.
METHOD: SPOT is a longitudinal, prospective, obser-
vational, programme. 2000 patients with mild to moder-
ate psoriasis will be recruited. (1000 Chronic Psoriasis
Patient & 1000 New Psoriasis Patient). The Psoriasis 
Disability Index [PDI] (Finlay AY et al 1987) and the SF
12 are evaluated every 3 months.
RESULTS: The preliminary results concern the analysis
of the ﬁrst 413 PDI scales completed at the inclusion visit.
The mean PDI score of the chronic psoriasis patients
(CPP) (n = 215) was 15,2 (sd 13,2) and the mean PDI
score of the new psoriasis patients (NPP) (n = 198) was
10,4 (sd 11,7) (p < 0.0001). When the sub-group of
retired and housewife patients was analysed there was no
difference in the scores between the CPP and NPP.
However, the sub-group consisting of salaried employees,
unemployed and sick leave patients showed a clear 
difference, mean PDI of CPP 14,4 (n = 149) compared to
NPP mean PDI = 9,7 (n = 158) (p = 0.0003). When all
questionnaires were analysed the “active population” are
less disabled than the “inactive group” (p < 0.05) and this
difference is also seen within the NPP (p < 0.05).
CONCLUSION: This ﬁrst analysis demonstrates the 
disability experienced by CPP and its greater impact on
the “active population”. This study will enable long-term
monitoring of the evolution of patients’ psoriasis and the
perception of patients concerning their management.
PES11
FUNCTIONAL LIMITATIONS IN THE US
ELDERLY POPULATION WITH VARYING LEVELS
OF VISUAL IMPAIRMENT
Lustig SP1, Shih YCT2, Prasad M2
1Pﬁzer Inc, Groton, CT, USA; 2MEDTAP International Inc,
Bethesda, MD, USA
OBJECTIVES: To examine the association between visual
impairment (VI) and functional limitations among the
elderly.
METHODS: Bivariate analyses were used to examine the
above associations. Data used in the analysis was the
Second Supplement on Aging (SOA II), a nationally rep-
resentative sample of the U.S. population aged 70 and
over in 1994. These cohort data of older Americans, col-
lected by the National Center of Health Statistics, are the
most recently released. VI identiﬁed from the data was
categorized into ﬁve forms: cataract, glaucoma, blindness
in one eye, blindness in both eyes, and trouble seeing 
even with glasses. Functional limitations were character-
ized by activities of daily living (ADLs), instrumental
activities of daily living (IADLs), and self-perceived health
status.
RESULTS: VI was found in 37.5% of persons aged 70
and over; among them 10% reported having more than
one form of VI. “Cataract” and “trouble seeing with
glasses”, alone or combined, accounted for approxi-
mately 68% of VI. On average, compared to the visually
unimpaired, the visually impaired group reported a sig-
niﬁcantly higher number of limitations in ADLs (diff =
0.52, P < 0.001) and IADLs (diff = 0.60, P < 0.001). A
signiﬁcantly higher proportion of the visually impaired
ranked their health status as poor (10.7% vs. 5.1%) and
a signiﬁcantly lower proportion reported “excellent”
(9.4% vs. 14.8%). Among the ﬁve forms of VI, the
average number of limitations in ADLs and IADLs were
highest among persons with blindness in both eyes (2.36
and 3.67, respectively), and were lowest in the glaucoma
group (0.86 and 0.89, respectively).
CONCLUSIONS: A positive and tangible association
existed between VI and more limited physical function-
ing as measured by ADLs and IADLs, and poorer self-
perceived health. Among the ﬁve forms of visual problems
examined, the most detrimental outcomes were found in
persons with blindness in both eyes.
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ANTIHISTAMINE UTILIZATION AND COSTS IN
PATIENTS WITH ATOPIC DERMATITIS
Kahler KH1, Pinkston P1, Freimark N2
1Novartis Pharmaceuticals Corporation, East Hanover, NJ,
USA; 2non-afﬁliated, Lakewood, NJ, USA
OBJECTIVE: Assess the antihistamine utilization and
associated costs in patients with atopic dermatitis (AD).
